Complete enrollment for the Phase 3 study of ALXN1840

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 24 Jul 2019
Due: 31 Mar 2020
Delivered: February 2020

Deadline
Met
Late
Not met
Today

What the company said

“Enrollment is expected to complete in early 2020.”

SourceAlexion Pharmaceuticals Form 8-K press release, 2019-07-24
FilingSEC filing index
Deadline as statedin early 2020
Deadline used31 Mar 2020, the last day of the stated period
TypeProject
Permanent referenceKI-C-2019-C899866-019331
Cite as https://keptindex.org/c/KI-C-2019-C899866-019331/ — this address never changes.

What we found

Evidence strength A What the grades mean

Alexion Pharmaceuticals completed enrollment for the Phase 3 study of ALXN1840 in February 2020, which falls within the early 2020 timeframe.

A
Alexion Pharmaceuticals 10-Q filed 2020-05-06 Regulatory filing · published 6 May 2020 · retrieved 21 Oct 2026 · kept permanently by the SEC · fingerprint b50cd3c17026
“In February 2020, Alexion completed enrollment in a Phase III study of ALXN 1840 for the treatment of Wilson disease.” ✓ confirmed on the page

Checked 21 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

1 versions

Version 1 · original · stated 24 Jul 2019

Deadline 31 Mar 2020 (“in early 2020”) · wording expected
Version 2 · stated 30 Jul 2020

Deadline 30 Jun 2021 (“in the first half of 2021”) · wording expected

“Study results are expected in the first half of 2021.”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical milestone
Indicative materiality: Medium rules
Action: Complete
Deliverable: Enrollment for Phase 3 study of ALXN1840
Language: Expected (“expects”, “plans”)
In the company’s control: Medium
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Alexion Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.